MedTrace Logo

Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment

NCT02265250 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-08-10

No results posted yet for this study

Summary

Cardiovascular disease (CVD) remains the leading cause of death in the United States, and improved CVD risk assessment is needed for personalized medicine. Atherosclerosis measures including plaque volume and adverse plaque features have prognostic value. Novel techniques have been developed for assessing carotid, coronary, and femoral atherosclerosis using magnetic resonance imaging (MRI) methods that are rapid and reproducible, have improved spatial resolution, and do not require contrast media, making atherosclerosis assessment in multiple vascular beds feasible during a single MRI session. This pilot research will provide preliminary data to develop an innovative global atherosclerosis measure including carotid, coronary, and femoral vascular beds, for assessing cardiovascular risk and for monitoring atherosclerosis response to therapy. 20 participants will be recruited in one year.

Conditions

Interventions

OTHER

MRI

Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries

OTHER

PET/MRI

Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries

OTHER

Laboratory blood test

Cardiovascular biomarkers

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Janet Wei, MD · Cedars-Sinai Medical Center

  • Noel Bairey Merz, MD · Cedars-Sinai Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02265250 on ClinicalTrials.gov